Merck says Phase 3 HYPERION trial shows WINREVAIR cuts PAH clinical worsening risk 76%

• Merck won a US label update for PAH drug Winrevair to add Phase 3 HYPERION efficacy and safety results.
• HYPERION results have already been presented via the updated label, supporting use soon after diagnosis alongside standard background therapy.
• Trial showed Winrevair cut the likelihood of clinical worsening versus placebo in recently diagnosed adults with intermediate-to-high progression risk.
• Label update adds safety language on hypersensitivity risk, monitoring for higher hemoglobin, lower platelets, bleeding, thromboembolic events.
• Disclosure broadens Winrevair’s clinical positioning earlier in the treatment pathway, reinforcing its role as an add-on option in PAH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260922788462) on September 22, 2026, and is solely responsible for the information contained therein.